Arrayjet Continue to Widen Global Sales Channels with New Distribution Deal
News Jun 07, 2013
Arrayjet Ltd has announced a new distribution deal with Sciencewerke Pte Ltd in South East Asia.
Arrayjet, a leader in microarray solutions, have expanded their global sales channels with the appointment of genomics and proteomics distributor Sciencewerke in South East Asia, with sales reach covering Singapore, Thailand, Malaysia and Indonesia.
Arrayjet has been in the microarray market since 2005 with the launch of the Marathon microarrayer, the first in a range of four microarray instruments utilizing the company's unique, non-contact inkjet technology.
Since then Arrayjet has developed the product range and diversified the offering with the launch of Arrayjet Advance microarray services in 2011.
Arrayjet Commercial Director, Claire Jenkins commented; ''with worldwide customers and a user base spanning 16 countries, selecting the right distribution partners is essential for Arrayjet. We are excited to have appointed Sciencewerke who have a great understanding of the microarray and biochip market in South East Asia. We look forward to working with them to support our existing customer base and to accelerate growth in this territory''.
Sciencewerke commented; ''we started out with a strong focus in microarray related products that included reagents and consumables for microarray labelling, substrates, array scanners, automated hybridization stations and bioinformatics software. Over the years, we’ve strengthened our product portfolio to also include a full suite of genomics services for microarray full service, NGS, low and high throughput SNP genotyping and more. With our knowledge, expertise and experience in microarray related products and services, and our strong presence in South East Asia, I’m sure we will be able to provide Arrayjet a strong springboard to propel and reach out to the clientele in this region''.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE